Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for…
Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, announced it has closed a…
Read More...
Read More...
